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Abstract  1 
Objectives  We conducted a cluster-randomised feasibility trial of 90-minute Chlamydia 2 
trachomatis tests and same day on-site treatment (“Test n Treat/TnT”) in six technical 3 
colleges in London, England to assess:  4 
 TnT uptake rates  5 
 Follow-up rates  6 
 Prevalence of C.trachomatis at baseline and 7-months 7 
 Time to treatment 8 
 Acceptability of TnT  9 
Methods 10 
Participants completed questionnaires and provided genitourinary samples at baseline and 11 
seven months. Participants were informed that baseline samples would not be tested for 7- 12 
months and advised to get screened independently. Colleges were randomly allocated 1:1 13 
to intervention (TnT) or control (no TnT). 14 
One and 4-months post-recruitment, participants at intervention colleges were texted 15 
invitations for on-site free C.trachomatis tests. A purposive sample of students who did/did 16 
not attend for screening were interviewed (n=26).  17 
Results 18 
509 sexually active students were recruited: median age 17.9 years, 47% male, 50% black 19 
ethnicity, 55% reporting ≥2 sexual partners in the previous year. TnT uptake was 13% 20 
(33/259; 95% CI 8.9-17.4%) at one month and 10% (26/259;6.7-14.4%) at 4-months with 21 
overall C.trachomatis positivity 5.1% (3/59;1.1-14.2%). Follow-up at 7-months was 62% 22 
(317/509) for questionnaires and 52% (264/509) for samples. C.trachomatis prevalence was 23 
6.3% (31/503) at baseline and 6.1% (16/264) at 7-months. Median time from test-to-24 
treatment was 15-hours. Interviews suggested low test uptake was associated with not 25 
feeling at risk, perceptions of stigma and little knowledge of sexually transmitted infections 26 
(STIs). 27 
Conclusions  28 
Despite high C.trachomatis rates at baseline and follow-up, uptake of testing was low. Like 29 
many countries, England urgently needs better sex education, including making STI testing 30 
routine/normal. 31 
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Introduction 1 
Chlamydia trachomatis is a common, often asymptomatic, bacterial sexually transmitted 2 
infection (STI) which can lead to pelvic inflammatory disease, ectopic pregnancy and 3 
infertility [1] [2] and may be associated with adverse pregnancy outcomes [3].  However, 4 
uptake of C.trachomatis testing by 16-24 year olds in many countries is too low to reduce 5 
infection rates [4-8] [1], and there are often delays in treatment. Bringing novel 90-minute 6 
C.trachomatis tests [9] [10] and same day on-site treatment (“TnT=Test n Treat”) to the 7 
community might get more young people treated faster [6, 10]. This could reduce rates of 8 
infection, onward transmission and adverse reproductive health effects, and save 9 
healthcare costs [7, 11]. 10 
 11 
In order to address a number of unknown parameters required for the design of a future 12 
definitive study, we conducted a cluster randomised feasibility trial (or pilot study) of 13 
frequent, rapid TnT in six technical (“Further Education”/ FE) colleges in London, England 14 
over the academic year 2016-17. (FE colleges offer both academic and practical courses such 15 
as plumbing and hairdressing, and take many students from socio-economically deprived 16 
backgrounds.  C.trachomatis positivity may be 6-8% [12-14].) 17 
We assessed the following feasibility outcomes: 18 
 Recruitment rates 19 
 TnT uptake rates  20 
 Follow-up rates  21 
 Prevalence of C.trachomatis at baseline and 7 months 22 
 Time to treatment 23 
 Acceptability of TnT  24 
 25 
We selected a cluster design for practical reasons for delivering screening, which would 26 
reflect the design of a definitive trial. This was a feasibility study and was not powered to 27 
assess the effectiveness of TnT. Although we used a combined C.trachomatis/Neisseria 28 
gonorrhoeae rapid test (Cepheid CT/NG GeneXpert® system [9]), on-site treatment (TnT) 29 
was for individuals with C.trachomatis only [15] as participants with N.gonorrhoeae (or 30 
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C.trachomatis/N.gonorrhoeae dual infection) were referred to a sexual health clinic. 1 
Detailed qualitative and economic analyses will be presented elsewhere.  2 
 3 
Methods 4 
Recruitment and baseline samples 5 
All technical colleges/clusters were eligible and all six approached agreed to participate. As 6 
previously described [15], researchers recruited students from public areas at the six 7 
colleges. Students were eligible if they were aged 16-24 and had ever had sexual 8 
intercourse. The participant information leaflet and consent form provided information 9 
about STIs and the study design (supplementary files). Participants provided written 10 
informed consent. They were asked to complete questionnaires (see Table 1), and to 11 
provide samples (for research purposes only) in the nearest washroom (urines for males, 12 
self-collected vaginal swabs for females) [15]. These samples were stored at -80 °C and 13 
tested blind at St George’s hospital after seven months using the Cobas 4800 CT/NG system 14 
(Roche diagnostics) [7]. All participants were warned of the risks of untreated 15 
C.trachomatis/N.gonorrhoeae and that their baseline samples would not be tested for seven 16 
months, and advised to get checked for STIs independently of the study.  17 
Randomisation 18 
After recruitment of all participants, the six colleges were randomly allocated 1:1 into the 19 
intervention group (TnT) or control group (no TnT, Figure 1) by the trial statistician using a 20 
computer-generated allocation sequence [15].  21 
 22 
Intervention colleges: TnT at both one and four months 23 
One and four months after recruitment (to fit with college Autumn and Spring terms), each 24 
of the three intervention colleges were visited on two consecutive days by the research 25 
team. We advertised the visit on college websites and notice boards, and texted/emailed 26 
participating students the day before the visit and on both days inviting them to come for 27 
TnT. Attendees came to a private room to collect a test kit. When they returned with a 28 
sample, it was tested for C.trachomatis/N.gonorrhoeae immediately on-site in a pop-up lab 29 
in a classroom using a 90-minute test [15] (one test/participant). Negative results were 30 
texted to participants. The research team’s nurse health-adviser telephoned participants 31 
6 
 
with positive results and met them in another private room in college (same-day whenever 1 
possible) for confidential treatment for C.trachomatis, partner notification and/or referral.  2 
 3 
Control colleges: no TnT  4 
Participants from the three control colleges received texts one and four months after 5 
recruitment thanking them for being in the study.  6 
 7 
Outcome assessment at 7 months 8 
All six colleges were visited again on two consecutive days in the summer term using the 9 
same methods as in TnT above, and participants from both groups were invited to provide 10 
repeat questionnaires and samples for immediate testing. Same day results and treatment 11 
were provided for all attenders (but these were not part of the TnT intervention). Non-12 
attenders were followed up by text/email and telephone questionnaire and asked to give an 13 
address (eg home/work/college) if they were willing to provide a postal sample for testing 14 
[15]. 15 
 16 
Honoraria 17 
Participants received £5 in cash when they returned samples at recruitment and £10 after 18 
providing samples at seven months follow-up. Participants in intervention colleges did not 19 
receive honoraria for attending for TnT at one and four months, as in the UK people are not 20 
usually paid for having an STI test.  21 
 22 
Masking 23 
Recruitment of colleges and participants was conducted blind to group allocation. After the 24 
first TnT intervention, participants and researchers were no longer blinded.  25 
 26 
Main outcome measures (key values to inform feasibility, sample size and timescales of a 27 
definitive trial) 28 
 Recruitment rates 29 
 TnT uptake in intervention participants at one and four-months  30 
 Follow-up rates at seven-months  31 
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 Prevalence of C.trachomatis at baseline and seven-months 1 
 Time to receiving results and treatment (fidelity of TnT) 2 
 Acceptability of TnT in intervention colleges from thematically-analysed semi-structured 3 
interviews[16] with purposively sampled students (n=26 to ensure a range of ages, 4 
genders and ethnicities) who did/did not attend for TnT (to be published elsewhere).  5 
 6 
Sample size and statistical analysis 7 
Sixty to 100 subjects is sufficient to estimate an event rate with acceptable precision (i.e. 8 
sufficiently narrow confidence intervals) in a feasibility study [17] [15]. As previously 9 
described [18], assuming a 30% recruitment rate [13], we aimed to approach 1600 students 10 
to recruit 480 overall (80 per college across 6 colleges).  11 
 12 
Progression criteria to a definitive trial were: TnT uptake ≥60% [13] at 1 and 4-months and 13 
TnT being acceptable to participants [16] (intervention colleges only), and follow-up rate 14 
≥70% [12] at 7-months (all colleges).  15 
 16 
Since this was a feasibility study, no significance testing was performed [19]. Descriptive 17 
statistics are presented, with corresponding exact 95% confidence intervals. Analyses [18] 18 
were performed in Stata version 14. As our analysis was of feasibility outcomes, the sample 19 
size and analysis were not adjusted for clustering. 20 
 21 
Ethics approval and consent to participate 22 
Bromley REC reviewed the study (reference 15/LO/1929). Parental consent for 16-18 year-23 
olds was not required. 24 
 25 
Results 26 
Recruitment 27 
Over three weeks in September/October 2016 we recruited 509 participants from six 28 
colleges (range 78-90 per college). We were unable to obtain information on all non-29 
participants, but completed recruitment forms for 180 non-participants suggested that 67%  30 
(121/180) were ineligible due to never having had sexual intercourse, 14% (25/180) were 31 
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ineligible for other reasons (e.g. not aged 16-24), and 19% (34/180) were eligible but 1 
declined.  2 
 3 
Participants’ median age was 17.9 years and 90% (458) were teenagers (aged 16-19 years). 4 
Participants described their ethnicity as black (50%), white (26%) or other ethnic groups 5 
(24%).  Approximately half (47%, 240) were male, including 117 (23%) black male teenagers. 6 
Over half (55%) reported ≥2 sexual partners in the previous year, and a third (36%) said they 7 
had been tested for STIs in the past 6 months. Eligible non-participants (n=34) were similar 8 
to participants in age and ethnicity (median age 17, IQR 17-19; 53% black ethnicity), but a 9 
slightly higher proportion (67%) were male. Table 1 shows baseline characteristics of 10 
participants from intervention and control colleges.  11 
 12 
TnT uptake at one and four months in intervention colleges 13 
Thirteen percent (33/259; 95% CI 8.9-17.4%) of intervention participants attended for on-14 
site rapid tests and provided samples at one month, and 10% (26/259; 95% CI 6.7-14.4%) at 15 
four months despite implementing changes suggested by students and staff to increase 16 
uptake. These included brief information for tutors to give to their tutorial groups, 17 
educational posters (supplementary files), user-friendly texts and free condoms. Five 18 
students provided samples at both one and four months. Of 59 tests, three (5.1%, 1.1-14.2) 19 
were positive for C.trachomatis. Two students with C.trachomatis only were treated on-site 20 
(one same day, one next day), and one with dual C.trachomatis/N.gonorrhoeae infection 21 
was referred for treatment as per protocol. Table 2 shows baseline characteristics of 22 
participants who did/did not provide samples for TnT were broadly similar, although more 23 
TnT attenders than non-attenders had a history of C.trachomatis (13% versus 6%), and more 24 
were men who had sex with men (MSM, 15% versus 3%). 25 
 26 
Follow-up 27 
Overall follow-up at seven months was 62% (317/509; 95% CI 58-67%) for questionnaires 28 
and 52% (264/509; 95% CI 47-56%) for samples. (A further four participants provided invalid 29 
samples: three with no human DNA, one delayed postal sample.) Almost half the 30 
participants (46%, 232/509) completed follow-up questionnaires at college, a further 9% 31 
(46/509) subsequently completed an online questionnaire and 8% (39/509) a brief 32 
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telephone questionnaire. These showed 29% of intervention participants and 25% of control 1 
participants reported STI testing outside the trial. (Other study-related behaviours reported 2 
at follow-up are shown in Table 3). Valid samples for testing were provided at college by 229 3 
(45%) participants and later by post by a further 35 (7%) participants. Supplementary Table 4 
1 gives baseline characteristics of those who did/did not provide samples at seven months 5 
follow-up.   6 
 7 
Prevalence of C.trachomatis/N.gonorrhoeae at baseline and 7-months 8 
Prevalences of C.trachomatis and N.gonorrhoeae respectively were 6.2% (31/503; 4.2-8.6%) 9 
and 0.6% (3/503, 0.1-1.7%) at baseline (six samples were discarded as mislabelled). 10 
Prevalences at follow-up were: C.trachomatis 6.1% (16/264, 3.5-9.7%, including 15 11 
C.trachomatis only positive samples [13 college, 2 postal] and one dual infection); and 12 
N.gonorrhoeae 1.1% (3/264, 0.2-3.3%, including the dual infection). The prevalence of 13 
C.trachomatis in males and females was 6.8% (16/236) and 5.6% (15/267) at baseline; and 14 
3.2% (4/125) and 8.6% (12/139) at follow-up. The three cases of N.gonorrhoeae at baseline 15 
were in males, the three at follow-up were in females. Prevalence of C.trachomatis in those 16 
tested at each college ranged from 1.3%-8.4% at baseline (intraclass correlation coefficient 17 
0.002), and 2.4%-10.4% at follow-up (Supplementary Table 2). 18 
 19 
Time to results and treatment  20 
For samples provided at college at one, four and seven months, most results (90%, 259/288) 21 
were received by participants the same day. Median time to being informed of a negative 22 
result (n=267) was 2.1 hours (IQR 1.8-2.7 hours, range 1.5 hours to 23 days due to an 23 
administrative error). For the 15 cases of C.trachomatis only which were diagnosed in 24 
college (2+13 at months one/four and seven respectively), ten were treated on-site (6 same 25 
day, 4 next day), three were confirmed treated later elsewhere (timing unclear for one), and 26 
two were not confirmed treated. Median time to confirmed treatment for C.trachomatis 27 
only (n=12) was 14.6 hours (IQR 2.4-26.3 hours, range 1.7 hours-27 days due to a problem 28 
with a mobile number).  29 
 30 
 31 
 32 
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Acceptability 1 
Semi-structured interviews in January-March 2017 with 13 students who attended for TnT 2 
and 13 who did not, suggested that low uptake of TnT was associated with not feeling at 3 
risk, perceptions of stigma and lack of knowledge about STIs. However, all were positive 4 
about TnT: “I think the service you provide is actually very good because like most kids I 5 
think they would be too shy to like go out and get checked….” (male, 16, black, TnT non-6 
attender). Comments from attenders included: “amazing”, “educational”, “friendly”, 7 
“helpful”.  8 
 9 
Discussion 10 
Principal findings 11 
Rapid recruitment of sexually active teenagers was possible with £5 honoraria. However, 12 
despite high rates of C.trachomatis at both baseline and follow-up, the proportion of 13 
participants attending for non-incentivised college-based TnT was low: 13% at one month 14 
and 10% at four months. Although predetermined progression criteria for a definitive trial 15 
were not met, findings provide important insights for designing future studies and for public 16 
health policy. 17 
 18 
Strengths and weaknesses 19 
This was a unique study in a group of often socio-economically deprived, ethnically diverse, 20 
inner city teenagers. It included >100 black, sexually experienced teenage males, a group 21 
not often included in European STI research studies [4, 7]. Participants had high rates of 22 
undiagnosed STIs including six participants with heterosexual N.gonorrhoeae, all from black 23 
and minority ethnic groups. It is also the first randomised study of rapid tests with on-site 24 
C.trachomatis treatment in FE colleges. It was a pragmatic study in a relevant setting to 25 
reach sexually active young people. Data on teenage lifestyles may inform future studies.  26 
 27 
There are limitations. Opportunistic recruitment meant it was difficult to calculate a 28 
recruitment rate. We could not use the college population aged 16-24 (range approximately 29 
500-3000 per college) as the denominator because assessment of eligibility required 30 
information on sexual history. As in other studies [4, 20] we used self-reported data, which 31 
is subject to inaccurate recall. However, reported history of C.trachomatis was similar to 32 
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rates in 16-24 year old Londoners taking part in the population-based National Surveys of 1 
Sexual Attitudes and Lifestyles (8.2%, 41/502 in our study versus 7.0%, 19/273 in Natsal-3 2 
UK data archive). Only two-thirds (10/15) of C.trachomatis only positives diagnosed in 3 
college were treated on-site. A faster 30 minute test might have encouraged more students 4 
to wait for results[21], but no such suitable test was available. Although all participants 5 
diagnosed with infections were informed that their partners needed treatment, we did not 6 
have partners’ consent to confirm notification. The study design meant TnT was only 7 
available to those already recruited. This would not happen if TnT were rolled out in routine 8 
practice. Follow-up rates were lower than the 81% in the recent “Safetxt” pilot trial[22], but 9 
most of their participants were white, and/or aged 20-24. Our findings may not apply to 10 
such groups.  11 
 12 
Comparison with other studies 13 
Rates of testing were lower than (54-60%) expected from our FE college-based pilot 14 
work[13, 16, 23], but similar to that in 16-29 year olds in a large Dutch register-based 15 
C.trachomatis screening trial: 16% in the first round decreasing to 11% in the second[8] with 16 
no substantial decrease in STI positivity rates. Another study from a Scottish FE college 17 
found 17% C.trachomatis testing uptake in teenagers[24] suggesting this is a challenging 18 
group to engage. By contrast, in the French Chlamyweb study [7] uptake by 18-24 year olds 19 
of an online offer of home-based C.trachomatis testing was 24% in males and 34% in 20 
females with positivity rates of 4.4% and 8.3% respectively. Similarly, in “SH24”, internet 21 
accessed postal testing almost doubled uptake of STI testing [20]. However most 22 
participants were white and/or aged 20-30 years. As in other studies [7] [16] many of our 23 
teenage participants did not want a test kit posted to their home. The high C.trachomatis 24 
positivity rates in Chlamyweb and our study were similar to those observed in STI clinics [7] 25 
and roughly double the rates in population-based studies in sexually-experienced males and 26 
females aged 16-24 in England [5] (2.3% and 3.1%) and USA [25] (1.7% and 3.2% 27 
respectively). Finally, there were more MSM among TnT attenders than non-attenders. 28 
MSM may be more aware of STI prevention [20].  29 
 30 
The median time from diagnosis to treatment (within one day) was similar to a recent 31 
feasibility study of online C.trachomatis management via an eSexual health clinic [26]. 32 
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Overall rates of confirmed treatment for C.trachomatis (87%, 13/15) were similar to 1 
ChlamywebII [7] (87%, 58/67) and 2014 English National Chlamydia Screening Programme 2 
results (91% within six weeks of test date [27]). Participants’ lack of knowledge about STIs 3 
was in line with community-based studies from USA, Europe and Australia [28] [29] [16, 24, 4 
30]. Sex education is optional in English state secondary schools. 5 
 6 
 7 
Conclusions and perspectives  8 
The low uptake of TnT despite high rates of STIs suggests that a definitive trial of TnT using 9 
this design is not feasible in FE colleges. It highlights both the difficulties of designing studies 10 
to reach sexually active young people, and the crucial need for better sex and relationships 11 
education [2]. This should include “normalisation” of STI testing [20] making it 12 
routine/acceptable to get checked. However, accessing testing is often problematic [1]. In 13 
the UK, funding cuts have closed many sexual health clinics, and relying on internet postal 14 
testing may disadvantage vulnerable teenagers [20]. Future trials might evaluate college-15 
wide, multicomponent, combined Education/TnT interventions. This could include lessons 16 
offering user-friendly information on STIs, free condoms and postal test kits perhaps 17 
followed by pop-up clinics offering confidential, on-site TnT. 18 
  19 
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Figure 1. Consort flow diagram for Test n Treat/TnT cluster randomised feasibility trial of 
rapid chlamydia tests and on-site treatment in six FE colleges 
 
 
 
 
 
 
 
 
  
Number of colleges  
n = 6  
Number of students recruited and 
provided samples at baseline 
n = 509 
 
TnT 
3 colleges 
259 students 
Control – no TnT 
3 colleges 
250 students 
 
1 month TnT* 
33 students tested 
 
4 months TnT* 
26 students tested 
 
Reasons no data at 7 months  
follow up (n=108) 
- Lost to follow-up (n=84) 
- Declined to provide 
sample/questionnaire 
(n=8) 
- Withdrawn/ hung up 
(n=9) 
- Agreed to provide sample 
but didn’t (n=7) 
 
7 months follow up 
Total – 151 students 
Samples –119 students** 
Questionnaire data - 150 students** * 
- College questionnaire (n=98) 
- Email questionnaire (n=26) 
- Telephone questionnaire (n=13) 
- Limited telephone questionnaire (n=13****) 
7 months follow up 
Total – 167 students 
Samples – 145 students** 
Questionnaire data - 167 students  
- College questionnaire (n=134) 
- Email questionnaire (n=20) 
- Telephone questionnaire (n=7) 
- Limited telephone questionnaire (n=6****) 
 
Reasons no data at 7 months 
follow up (n=83) 
- Lost to follow-up (n=64) 
- Declined to provide 
sample/questionnaire (n=2) 
- Withdrawn/ hung up (n=9) 
- Agreed to provide sample 
but didn’t (n=8) 
 
*Five participants provided samples at both one and four months. 
** Two additional samples from each arm did not give a valid result  
*** One participant only returned a sample but did not complete a questionnaire  
**** Limited questionnaire data were collected while informing participants by telephone of a 
positive baseline test for five and two individuals in the intervention and control groups 
respectively. 
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Table 1: Baseline characteristics of 509 Further Education college students allocated to 
intervention and control arms of the Test and Treat C.trachomatis screening trial.  
Characteristic 
 Intervention  Control 
 (n=259)  (n=250) 
   
Male % (n) 49.8 (129)  44.4 (111) 
   
Age median (IQR) 17.6 (16.8-18.6) 18.0 (17.3-18.9 
   
Ethnicity % (n)   
White 27.2 (70)  25.5 (63) 
Black African/Black Caribbean/Black British 48.6 (125)  51.0 (126) 
Asian/Asian British  5.1 (13)   6.1 (15) 
Mixed/multiple ethnicities 15.2 (39)  12.6 (31) 
Other ethnic group  3.9 (10)   4.9 (12) 
   
Sexual Preference (females)  % (n)   
Sex with men only 86.8 (112)  89.9 (124) 
Sex with women only  3.9 (5)   1.4 (2) 
Sex with men and women  4.7 (6)   7.2 (10) 
Prefer not to say  4.7 (6)   1.4(2) 
Sexual Preference (males)  % (n)   
Sex with men only  3.9 (5)   2.7 (3) 
Sex with women only 93.0 (120)  94.6 (105) 
Sex with men and women  1.6 (2)   2.7 (3) 
Prefer not to say  1.6 (2)   0.0 (0) 
   
Age at first sexual intercourse <16 years % (n) 44.8 (112) 47.3 (112) 
   
Two or more partners in past 12 months % (n) 56.6 (145) 53.5 (130) 
   
New sexual partner in past 6 months % (n) 55.5 (141) 51.4 (128) 
   
Female contraception % (n)   
Condoms 56.2 (73) 54.0 (75) 
Pill 16.9 (22) 20.9 (29) 
Implant/coil 15.4 (20) 17.3 (24) 
None 20.0 (26) 15.1 (21) 
Other  2.3 (3)  2.9 (4) 
Condom use (male and female) % (n)   
Always 36.2 (92) 36.0 (89) 
Usually 17.7 (45) 21.1 (52) 
Sometimes 31.1 (79) 26.3 (65) 
Never 15.0 (38) 
16.6 (41) 
 
Last STI check  % (n)   
Never 46.1 (118) 41.9 (103) 
In the past 6 months 36.7 (94) 35.8 (88) 
More than 6 months ago 17.2 (44) 22.4 (55) 
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STI history ever % (n)   
C.trachomatis  7.5 (19)  8.9 (22) 
N.gonorrhoeae  5.7 (14)  4.2 (10) 
Other STI  0.9 (2)  1.3 (3) 
NSU  0.4 (1)  1.3 (3) 
Pelvic Inflammatory Disease in past 6 months 
(females only)  2.4 (3)  2.2 (3) 
 
Symptoms in past 6 months (female) % (n)   
Bleeding between periods 17.5 (21) 15.9 (21) 
Abnormal vaginal discharge 11.9 (14) 14.8 (19) 
Pelvic discomfort other than normal period pain  7.0 (8) 13.2 (17) 
Pain during sex 17.4 (20) 17.3 (23) 
Symptoms in past 6 months (male) % (n)   
Pain/ burning when urinating  6.5 (8)  7.4 (8) 
Discharge from your penis  2.4 (3)  1.9 (2) 
Pain or discomfort in testicles  6.5 (8)  4.7 (5) 
Pain/ burning from back passage  2.5 (3)  1.9 (2) 
   
Smokes cigarettes % (n) 34.3 (87) 32.4 (81) 
Alcohol-reports was drunk in past month % (n) 48.4 (123) 48.3 (119) 
   
Visited GP in past 6 months % (n) 59.1 (149) 61.6 (151) 
Visited Sexual health clinic in past 6 mths % (n) 31.2 (79) 29.6 (72) 
Visited Walk-in clinic in past 6 months % (n) 29.1 (73) 31.6 (77) 
Visited A&E/hospital in past 6 months % (n) 36.0 (91) 31.8 (78) 
   
Attended healthcare facility for sexual health 
reasons in the past 6 months % (n) 36.9 (94) 35.4 (87) 
C.trachomatis at baseline* % (n) 7.1 (18) 5.2  (13) 
N.gonorrhoeae at baseline* % (n) 1.2 (3) 0    (0) 
*Baseline samples were stored and tested after seven months.  
Similar numbers of students were recruited from each college (intervention colleges n=84, 85, 
90; total 259: control colleges n=83, 78, 89; total 250). 
NSU: non-specific urethritis. GP: general practitioner. A&E: Accident and Emergency department 
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Table 2: Baseline characteristics of 259 intervention students who either attended 
TnT and provided samples, or did not attend TnT at 1 month and/or 4 months 
 
Baseline characteristic  Attended TnT  Did not attend TnT 
 (n=54*)  (n=205) 
Male % (n)     
  48.1 (26) 50.2 (103) 
     
Age median (IQR)  17.4 (16.7 to 18.7) 17.7 (16.8 to 18.5) 
Ethnicity % (n)    
White  28.8 (15) 26.8 (55) 
Black African/Black Caribbean/Black British  51.9 (27) 47.8 (98) 
Asian/Asian British   1.9 (1)  5.9 (12) 
Mixed/multiple ethnicities  13.5 (7) 15.6 (32) 
Other ethnic group   3.8 (2)  3.9 (8) 
     
Sexual Preference (females)  % (n)    
Sex with men only  100.0 (27) 83.3 (85) 
Sex with women only   0.0 (0)  4.9 (5) 
Sex with men and women   0.0 (0)  5.9 (6) 
Prefer not to say   0.0(0)  5.9 (6) 
Sexual Preference (males)  % (n)    
Sex with men only   7.7 (2)  2.9 (3) 
Sex with women only  84.6 (22) 95.1 (98) 
Sex with men and women   7.7 (2)  0.0 (0) 
Prefer not to say   0.0 (0)  1.9 (2) 
     
Age first sex <16 years % (n) 44.2 (23) 44.9 (89) 
    
Two or more partners in past 12 months % (n) 50.9 (27) 58.1 (118) 
    
New partner in past 6 months % (n) 50.9 (27) 56.7 (114) 
    
Female contraception % (n)    
Condoms 67.9 (19) 52.9 (54) 
Pill 14.3 (4) 17.6 (18) 
Implant/coil 14.3 (4) 15.7 (16) 
None 14.3 (4) 21.6 (22) 
Other  7.1 (2)  1.0 (1) 
Condom use (male and female) % (n)    
Always 41.5 (22) 34.8 (70) 
Usually 17.0 (9) 17.9 (36) 
Sometimes 30.2 (16) 31.3 (63) 
Never 11.3 (6) 15.9 (32) 
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Last STI check % (n)    
Never 45.3 (24) 46.3 (94) 
In the past 6 months 35.8 (19) 36.9 (75) 
More than 6 months ago 18.9 (10) 16.7 (34) 
STI ever % (n)    
C.trachomatis 13.2 (7)  6.0 (12) 
N.gonorrhoeae  8.2 (4)  5.1 (10) 
Other STI  0.0 (0)  1.0 (2) 
NSU  0.0 (0)  0.5 (1) 
Pelvic Inflammatory Disease in past 6 months 11.1 (3)  0.0 (0) 
Symptoms in past 6 months (female) % (n)    
Bleeding between periods 25.0 (6) 15.6 (15) 
Abnormal vaginal discharge 12.5 (3) 11.7 (11) 
Pelvic discomfort other than normal period pain  8.7 (2)  6.6 (6) 
Pain during sex 14.3 (3) 18.1 (17) 
Symptoms in past 6 months (male) % (n)    
Pain/ burning when urinating  4.0 (1)  7.1 (7) 
Discharge from your penis  0.0 (0)  3.1 (3) 
Pain or discomfort in testicles  8.0 (2)  6.1 (6) 
Pain/ burning from back passage  4.2 (1)  2.1 (2) 
     
Smokes cigarettes % (n) 22.6 (12) 37.3 (75) 
     
    
Alcohol-reports was drunk in past month % 
(n) 43.2 (22) 49.8 (101) 
    
Visited GP in past 6 months % (n) 53.8 (28) 60.5 (121) 
Visited sexual health clinic in past 6 months % (n) 39.2 (20) 29.2 (59) 
Visited Walk-in clinic in past 6 months % (n) 30.0 (15) 28.9 (58) 
Visited A&E/hospital in past 6 months % (n) 27.5 (14) 38.1 (77) 
    
Attended healthcare facility for sexual health 
reasons in past 6 months % (n) 46.2 (24) 34.5 (70) 
 
C.trachomatis at baseline % (n)  3.7 (2)  8.0 (16) 
N.gonorrhoeae at baseline % (n)  0.0 (0)  1.5 (3) 
 
* Five participants attended at both one and four months  
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Table 3: Reported behaviours during the study from 7-month follow-up questionnaires  
  
 Intervention  Control  
Follow-up characteristics,  % (n) (n=150) (n=167) 
Follow up method       College questionnaire 65.3 (98) 80.2 (134) 
 Email questionnaire 17.3 (26) 12.0 (20) 
Telephone questionnaire 8.7 (13) 4.2 (7) 
Limited telephone questionnaire 8.7 (13) 3.6 (6) 
     
 
Have they had sex with anyone new 
since last visit? 
 
Yes 49.3 (73) 54.5 (91) 
Have they been tested for 
chlamydia or gonorrhoea outside 
the study? 
     
Yes 29.3 (44) 25.1 (42) 
     
Where did they get tested? GP 21.2 (7) 12.8 (5) 
 Sexual health clinic 33.3 (11) 56.4 (22) 
Walk in clinic 9.1 (3) 5.1 (2) 
 Hospital 3.0 (1) 2.6 (1) 
 College 27.3 (9) 17.9 (7) 
 Other 6.1 (2) 5.1 (2) 
     
Smoking (cigarettes per 
day) 
None 69.7 (83) 65.5 (91) 
 1-10 25.2 (30) 30.9 (43) 
 More than 10 5.0 (6) 3.6 (5) 
     
Vape (smoke electronic cigarettes) No 85.9 (110) 84.7 (133) 
   Yes 6.3 (8) 4.5 (7) 
Occasionally 7.8 (10) 10.8 (17) 
     
Alcohol (number of times drunk in 
past month) 
None 61.7 (79) 51.3 (80) 
1-4 times  28.9 (37) 41.0 (64) 
 5 or 
more 
9.4 (12) 7.7 (12) 
     
Visited GP in past 6 months  56.4 (75) 49.4 (79) 
Visited GUM clinic in past 6 months  22.1 (29) 25.8 (41) 
Visited Walk-in clinic in past 6 months 22.1 (29) 25.6 (40) 
Visited A&E/hospital in past 6 months 
 
28.8 (38) 23.1 (37) 
Attended healthcare facility for sexual health 
reasons 
15.1 (39) 17.2 (43) 
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Supplementary Table 1. Baseline characteristics of 509 participants who did or did not 
provide a valid sample at 7 months follow-up. 
Baseline characteristic 
Sample provided 
at follow-up 
 No sample at 
follow-up 
  (n=264)  (n=245) 
Male % (n)   
  47.3 (125) 46.9 (115) 
   
Age median (IQR) 
 
 17.9 (17.1 to 
18.7) 
17.9 (16.9 to 
18.7) 
Ethnicity % (n)   
White  26.6 (69) 26.6 (64) 
Black African/Black Caribbean/Black British  52.1 (135) 47.3 (116) 
Asian/Asian British   6.2 (16) 4.9 (12) 
Mixed/multiple ethnicities  10.4 (27) 17.6 (43) 
Other ethnic group   4.6 (12)  4.1 (10) 
   
Sexual Preference (females)  % (n)   
Sex with men only  87.7 (121) 89.1 (115) 
Sex with women only   1.4 (2)  3.9 (5) 
Sex with men and women   6.5 (9)  5.4 (7) 
Prefer not to say   4.3 (6)  1.6 (2) 
Sexual Preference (males)  % (n)   
Sex with men only   4.0 (5)  2.6 (3) 
Sex with women only  92.8 (116) 94.8 (109) 
Sex with men and women   2.4 (3)  1.7 (2) 
Prefer not to say   0.8 (1)  0.9 (1) 
   
Age first sex <16 years % (n) 42.3 (107) 50.0 (117) 
   
Two or more partners in past 12 months % (n) 53.1 (136) 57.2 (139) 
   
New partner in past 6 months % (n) 50.4 (132) 56.8 (137) 
   
Female contraception % (n)   
Condoms 57.6 (80) 52.3 (68) 
Pill 22.3 (31) 15.4 (20) 
Implant/coil 14.4 (20) 18.5 (24) 
None 16.5 (23) 18.5 (24) 
Other  2.9 (4)  2.3 (3) 
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Condom use (male and female) % (n) 
Always 37.1 (99) 35.1 (85) 
Usually 18.1 (47) 20.7 (50) 
Sometimes 31.7 (82) 25.6 (62) 
Never 13.1 (34) 18.6 (45) 
   
Last STI check up % (n)   
Never 46.5 (121) 41.3 (100) 
In the past 6 months 35.4 (92) 37.2 (90) 
More than 6 months ago 18.1 (47) 21.5 (52) 
STI history % (n)   
C.trachomatis  6.5 (17) 10.0 (24) 
N.gonorrhoeae  3.1 (8)  6.9 (16) 
Other STI  0.8 (2)  1.3 (3) 
NSU  0.4 (1)  1.3 (3) 
Pelvic Inflammatory Disease in past 6 months  2.9 (4)  1.6 (2) 
 
Symptoms in past 6 months (female) % (n)   
Bleeding between periods 14.8 (19) 18.5 (23) 
Abnormal vaginal discharge 16.0 (20) 10.7 (13) 
Pelvic discomfort other than normal period pain 10.6 (13) 10.0 (12) 
Pain during sex 18.3 (23) 16.4 (20) 
   
Symptoms in past 6 months (male) % (n)   
Pain/ burning when urinating  7.4 (9)  6.4 (7) 
Discharge from your penis  1.7 (2)  2.8 (3) 
Pain or discomfort in testicles  5.0 (6)  6.4 (7) 
Pain/ burning from back passage  2.5 (3)  1.9 (2) 
   
Smokes cigarettes % (n) 27.5 (72) 39.7 (96) 
   
Alcohol-reports was drunk in past month % (n) 46.3 (120) 50.6 (122) 
   
Visited GP in past 6 months % (n) 62.0 (160) 58.5 (140) 
Visited sexual health clinic in past 6 months % (n) 28.8 (74) 32.2 (77) 
Visited Walk-in clinic in past 6 months % (n) 32.3 (83) 28.2 (65) 
Visited A&E/hospital in past 6 months % (n) 31.5 (81) 36.5 (88) 
   
Attended healthcare facility for sexual health reasons in past 6 
months % (n) 35.1 (91) 37.2 (90) 
   
C.trachomatis at baseline % (n)  3.8(10)  8.7 (21) 
N.gonorrhoeae at baseline % (n)  0.4 (1)  0.8 (2) 
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Supplementary Table 2: Prevalence of C. trachomatis at baseline and final seven months 
follow-up in three intervention and three control colleges 
 
 Intervention 
college 1 
Intervention 
college 2 
Intervention 
college 3 
Control 
college 1 
Control 
college 2 
Control 
college 3 
Prevalence of 
C.trachomatis 
at baseline 
% (n/N) 
8.3  
(7/84) 
8.3  
(7/84) 
4.6  
(4/87) 
8.4  
(7/83) 
1.3  
(1/77) 
5.7  
(5/88) 
Prevalence of 
C.trachomatis   
at seven 
months 
follow up 
% (n/N) 
5.1  
(2/39) 
7.7  
(3/39) 
2.4  
(1/41) 
4.1  
(2/49) 
6.3  
(3/48) 
10.4  
(5/48) 
 
 
 
